Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (not Talpher, Inc.) on October 18, 2023. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's continued listing status on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq stating that the Company's common stock failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180 calendar days to regain compliance. The deadline to demonstrate compliance is April 15, 2024.
- Requirements: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days within the compliance period.
- Delisting Risk: If the Company fails to regain compliance within the initial 180 days, it may be eligible for a second 180-day period if it meets other listing standards (excluding the bid price) and intends to cure the deficiency, potentially via a reverse stock split. Failure to cure the deficiency ultimately results in delisting.
- Management Action: Management intends to actively monitor the stock price and evaluate available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of AcelRx Pharmaceuticals, Inc. (ACRX) to assess proximity to the $1.00 threshold.
- Monitor future announcements regarding the potential implementation of a reverse stock split.
- Confirm the company's status regarding the April 15, 2024, compliance deadline.
- Review the company's cash position in other filings to determine if a reverse stock split is financially viable if required.